Canyon Pharmaceuticals Honored with Frost & Sullivan Award for Product Differentiation Excellence in Parenteral Anticoagulants

PARSIPPANY, N.J.--(BUSINESS WIRE)--The Frost & Sullivan 2011 Product Differentiation Excellence Award in Parenteral Anticoagulants recognizes Canyon Pharmaceuticals Group AG for the development and launch of Iprivask® (desirudin for injection). “Iprivask has been shown to prevent thrombosis significantly more effectively than the standard of care, with no increase in bleeding risk. A simplified fixed dose regimen and easy subcutaneous administration coupled with an attractive pharmacological profile make Iprivask ideally suited for the acute care setting, a space in need of safe, effective and user friendly therapies. Through careful product differentiation during development, Canyon Pharmaceuticals has succeeded in uniquely positioning Iprivask to be very competitive in an increasingly crowded market,” noted Frost & Sullivan Analyst Debbie Toscano.